Onconova Therapeutics
Founded Year
1998Stage
IPO | IPOTotal Raised
$165.63MDate of IPO
7/25/2013Market Cap
0.02BStock Price
1.09Revenue
$0000About Onconova Therapeutics
Onconova Therapeutics, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The companys clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates that target kinases, cellular metabolism, or cell division in preclinical development.
Onconova Therapeutics Headquarter Location
375 Pheasant Run
Newtown, Pennsylvania, 18940,
United States
267-759-3680
Expert Collections containing Onconova Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Onconova Therapeutics is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Onconova Therapeutics Patents
Onconova Therapeutics has filed 12 patents.
The 3 most popular patent topics include:
- Experimental cancer drugs
- Fluoroarenes
- Abandoned drugs
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/6/2013 | 3/3/2020 | Transcription factors, Oncology, Rare diseases, Experimental cancer drugs, Antineoplastic drugs | Grant |
Application Date | 12/6/2013 |
---|---|
Grant Date | 3/3/2020 |
Title | |
Related Topics | Transcription factors, Oncology, Rare diseases, Experimental cancer drugs, Antineoplastic drugs |
Status | Grant |
Latest Onconova Therapeutics News
Apr 27, 2022
About Onconova Therapeutics Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer. For more information, please visit www.onconova.com . Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “preliminary,” “encouraging,” "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:
Onconova Therapeutics Web Traffic
Onconova Therapeutics Rank
When was Onconova Therapeutics founded?
Onconova Therapeutics was founded in 1998.
Where is Onconova Therapeutics's headquarters?
Onconova Therapeutics's headquarters is located at 375 Pheasant Run, Newtown.
What is Onconova Therapeutics's latest funding round?
Onconova Therapeutics's latest funding round is IPO.
How much did Onconova Therapeutics raise?
Onconova Therapeutics raised a total of $165.63M.
Who are Onconova Therapeutics's competitors?
Competitors of Onconova Therapeutics include Kiadis Pharma, Aquinox Pharmaceuticals, Neuraltus Pharmaceuticals, Radius Health, TetraLogic Pharmaceuticals and 13 more.
You May Also Like
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
Cardeon Corporation is engaged in developing solutions for stroke prevention
FGI, based in Rockville, Maryland, is developing drugs and diagnostics based on its genome-wide discovery and validation of genes and their roles in human disease. FGI has validated drug candidates for the treatment of infectious disease, drug resistant cancer and Alzheimer's disease.
Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.
Free Radical Scavengers developed from Duke's BME Department for treating and preventing diseases from occurring.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.